An interventional study of Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic) and CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens in Myopia, sponsored by Bausch & Lomb Incorporated. Recruiting at 11 sites in China. Open to participants aged 8 Years to 12 Years. Per ClinicalTrials.gov, last updated 2025-06-15.
Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Myopia by Bausch Health Companies Inc. — 3 open to participants now, 3 under way, none of them phase 3. Myopia · Bausch Health Companies Inc..
Among the 43 studies in Myopia by Bausch Health Companies Inc., this one is the 7th largest by planned enrollment, is the only one that started in 2024, is one of 35 with no phase, and was the 41st registered.
1,165 studies on the registry are indexed under Myopia; 228 are open to participants now.
Browse Myopia studies →3 of the 43 studies in Myopia by Bausch Health Companies Inc. are open now, in 2 countries. Recruiting first, the newest first:
Bausch & Lomb GmbH · Sites in Czechia
Ages 18+
Bausch & Lomb Incorporated
Ages 22+
By country, each count listing its studies:
Of the 123 Myopia studies recruiting now, 19 (15%) set no upper age limit and 103 (84%) stop at 75 or younger; 85 take children under 18; 52 take healthy volunteers.
This study: 8 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2024.
This study's planned enrollment of 418 is above the median of 79 across 928 interventional studies indexed under Myopia.
Median enrollment 140 across the 43 interventional studies. Of the 35 that completed or were terminated, 31 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Bausch & Lomb Incorporated, one of the names counted as Bausch Health Companies Inc.. Under that name alone:
Bausch & Lomb Incorporated is the lead sponsor of 223 studies on the registry; 5 are open to participants now.
Of its 51 completed or terminated interventional studies of FDA-regulated products, 41 (80%) have results posted.
3 of the studies in Myopia by Bausch Health Companies Inc. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06618547Bausch & Lomb IncorporatedEffectiveness and Safety of the TENEO 317 Model 2 Excimer Laser to Treat Myopia With or Without Astigmatism by Transepithelial Photorefractive Keratectomy | 2026-11 |
| NCT06305663Bausch & Lomb IncorporatedA Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children | 2027-01-31 |
| NCT06997003Bausch & Lomb GmbHEvaluation of a New Laser Refractive Vision Correction Using the TENEO™ 317 Model 2 | 2027-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 43 studies in Myopia by Bausch Health Companies Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children
A Multi-center, Randomized, Parallel, Bilateral, Investigator-masked study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject must meet the following determined by cycloplegic subjective refraction in both eyes at screening:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic)
Device: CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens
Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic)
CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens
Mean change from baseline in axial length.
Mean change from baseline in axial length will be evaluated at the one-year and two-year visits.
Time frame: 1 and 2 years
Mean change from baseline in cycloplegic SERE.
Mean change from baseline in cycloplegic SERE will be evaluated at the one-year and two-year visits.
Time frame: 1 and 2 years
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Started Mar 2024 (actual). Primary completion is estimated for Jan 2027, 34 months after the start.
Of 236 industry-sponsored interventional studies with no phase under Myopia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's planned 34 months is above that.
Counting every sponsor, half of 437 studies reached it within 14 months; a quarter within 3 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.